Genedata: The Digital Status Quo for Research and Development
pharmatechoutlook

Genedata: The Digital Status Quo for Research and Development

Follow Genedata on :

Dr. Othmar Pfannes, CEO, GenedataDr. Othmar Pfannes, CEO
The biopharmaceutical industry stands at the juncture of a paradigm shift toward digitalization of research and development waiting to happen. In a traditional high content image analysis, scientists have to design the patterns by observing hundreds of features, including cell size or fluorescence intensity, when using labeled proteins. Repeating this process over millions of samples can be tedious and takes up a lot of time. For this reason, biopharmaceuticals are looking into deep learning as the next step in redefining the field of research and development and cutting down the time required for return of investment. A company called Genedata emerges as a gamechanger by transforming data into intelligence with its innovative software solutions and services that support large-scale, experimental processes in life science research, large assay type screening, multi-omic profiling, biologics, spectrometry, and other functions of a biopharmaceutical enterprise.

Genedata has developed an innovative high-content screening (HCS) or image analysis workflow called Genedata Imagence, based on deep learning that shortens the time required for the procedure while increasing data quality and reproducibility of reports. It automates repetitive tasks during the setup, detects complex phenotypes, and increases reproducibility by eliminating the biased selection of handcrafted features. Genedata Imagence widely outperforms the conventional methods of feature extraction and phenotype classification by using revolutionary machine learning techniques. Genedata Imagence enables biologists to quickly set up HCS campaigns and analyze it without the assistance of an image analysis expert. It can classify HCS image sets for training purpose, quantify relevant pharmacology, and produce top quality results, quicker than other legacy systems.
“Genedata Imagence is revolutionizing a key process in biopharmaceutical R&D,” says Dr. Othmar Pfannes, CEO, Genedata.

Some of the products of Genedata, such as Screener and Imagence are seamlessly integrated with each other. Genedata Screener analyzes, visualizes, and manages screening data from in-vitro screening assay technologies, for the entire enterprise. Genedata Profiler enables biologists to compile and combine large amounts of patient profiles with other data received in order to provide precise medication to patients. Genedata Biologics is a platform which supports large molecule research process such as screening, protein engineering and optimization, analysis, quality control, candidate development, and manufacture assessment. It supports the design and engineering of therapeutic molecules and identifies the best molecule to move forward with. Genedata Expressionist software revolutionizes the data processing, analysis, management, and reporting of metabolomics, proteomics, and biotherapeutics characterization studies based on mass spectrometry.

If a user requires an enterprise workflow platform that enables the cost-efficient development of next-generation bio-manufacturing processes, Genedata Bioprocess is best suited for such needs. Genedata Selector is an open platform that is built with the idea of seamless integration with any corporate IT infrastructure. For premium users, Genedata Analyst is a solution for the integration and interpretation of experimental data in life science research and development. It applies rigorous statistical algorithms, data analysis tools, and intuitive visualization into the hands of researchers. Genedata Analyst supports any scale of users on standard hardware, with server-side sessions guaranteeing security and facilitates consistent knowledge-sharing company-wide.

“Genedata remains committed to supporting innovative research projects in academic and industrial partnerships with its scalable and flexible bioinformatics platforms,” says Dr. Pfannes. Depending upon the customer’s needs, Genedata’s innovative enterprise solutions can be deployed to a variety of infrastructures, including on-premises or cloud-based installations. With widespread offices throughout Europe, the U.S., and Asia, Genedata employs more than 200 scientific and computational experts. The company continues to invest in its passion for helping customers control research and development costs as they develop next-generation products and therapies.